Hiroyuki Misawa
Director/Board Member at REGiMMUNE Corp.
Profile
Hiroyuki Misawa is currently a Director at REGiMMUNE Corp., CellAxia, Inc., ARTham Therapeutics, Inc., and a Partner at Miyako Capital KK.
He was previously a Director-Investment Group at Japan Asia Investment Co., Ltd.
Misawa received his undergraduate, graduate, and doctorate degrees from Saitama University.
Hiroyuki Misawa active positions
| Companies | Position | Start |
|---|---|---|
REGiMMUNE Corp.
 REGiMMUNE Corp. Pharmaceuticals: MajorHealth Technology REGiMMUNE Corp. develops solutions for treating immune disorders. Its focus is on the discovery, development, and commercialization of immune regulatory therapeutics to treat life-threatening and debilitating conditions, including allergies, autoimmune diseases and transplantation. The firm's platform technology, reVax, induces immune tolerance in an antigen-specific manner through pharmacological induction of regulatory T (Treg) cells. It also develops products for preventing inhibitor formation in enzyme replacement therapies (ERT) and for celiac disease with undisclosed partners. The company was founded by Yasuyuki Ishii on March 3, 2006 and is headquartered in Tokyo, Japan. | Director/Board Member | - |
Miyako Capital KK
 Miyako Capital KK Investment ManagersFinance Miyako Capital KK (Miyako Capital) is an Independent Private Equity/Venture Capital firm founded in 2013 by Satoshi Yamaguchi and Hiroaki Okahashi. Miyako Capital KK is headquartered in Kyoto. | Private Equity Investor | - |
ARTham Therapeutics, Inc.
 ARTham Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Kaken Pharmaceutical Co., Ltd., ARTham Therapeutics, Inc. is a pharmaceutical company based in Yokohama, Japan. The Japanese company's mission is to deliver "medicines that matter" to improve patient health and contribute to enhanced quality of life through the development of innovative disease-modifying medicines. The company was founded by Sham Nikam, Naoto Uemura, and has been led by CEO Hiroshi Nagabukuro since 2018. ARTham Therapeutics was acquired by Kaken Pharmaceutical Co., Ltd. on December 13, 2021 for $111.95 million. | Director/Board Member | - |
CellAxia, Inc.
 CellAxia, Inc. Pharmaceuticals: MajorHealth Technology CellAxia, Inc. is a Japanese company that engages in research and development, manufacturing, and selling of pharmaceutical products. The company is based in Tokyo, Japan. The company was founded in 2017 by Makoto Seki. | Director/Board Member | - |
Former positions of Hiroyuki Misawa
| Companies | Position | End |
|---|---|---|
| JAPAN ASIA INVESTMENT CO., LTD. | Corporate Officer/Principal | - |
Training of Hiroyuki Misawa
| Saitama University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| JAPAN ASIA INVESTMENT CO., LTD. | Finance |
| Private companies | 4 |
|---|---|
REGiMMUNE Corp.
REGiMMUNE Corp. Pharmaceuticals: MajorHealth Technology REGiMMUNE Corp. develops solutions for treating immune disorders. Its focus is on the discovery, development, and commercialization of immune regulatory therapeutics to treat life-threatening and debilitating conditions, including allergies, autoimmune diseases and transplantation. The firm's platform technology, reVax, induces immune tolerance in an antigen-specific manner through pharmacological induction of regulatory T (Treg) cells. It also develops products for preventing inhibitor formation in enzyme replacement therapies (ERT) and for celiac disease with undisclosed partners. The company was founded by Yasuyuki Ishii on March 3, 2006 and is headquartered in Tokyo, Japan. | Health Technology |
Miyako Capital KK
Miyako Capital KK Investment ManagersFinance Miyako Capital KK (Miyako Capital) is an Independent Private Equity/Venture Capital firm founded in 2013 by Satoshi Yamaguchi and Hiroaki Okahashi. Miyako Capital KK is headquartered in Kyoto. | Finance |
ARTham Therapeutics, Inc.
ARTham Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Kaken Pharmaceutical Co., Ltd., ARTham Therapeutics, Inc. is a pharmaceutical company based in Yokohama, Japan. The Japanese company's mission is to deliver "medicines that matter" to improve patient health and contribute to enhanced quality of life through the development of innovative disease-modifying medicines. The company was founded by Sham Nikam, Naoto Uemura, and has been led by CEO Hiroshi Nagabukuro since 2018. ARTham Therapeutics was acquired by Kaken Pharmaceutical Co., Ltd. on December 13, 2021 for $111.95 million. | Health Technology |
CellAxia, Inc.
CellAxia, Inc. Pharmaceuticals: MajorHealth Technology CellAxia, Inc. is a Japanese company that engages in research and development, manufacturing, and selling of pharmaceutical products. The company is based in Tokyo, Japan. The company was founded in 2017 by Makoto Seki. | Health Technology |
- Stock Market
- Insiders
- Hiroyuki Misawa
